Genelux (NASDAQ: GNLX) recently received a number of ratings updates from brokerages and research firms:
- 10/21/2025 – Genelux was given a new $20.00 price target on by analysts at Maxim Group.
- 10/21/2025 – Genelux was given a new $16.00 price target on by analysts at Loop Capital.
- 10/21/2025 – Genelux is now covered by analysts at Lake Street Capital. They set a “buy” rating and a $16.00 price target on the stock.
- 10/8/2025 – Genelux had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 9/27/2025 – Genelux had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Further Reading
- Five stocks we like better than Genelux
- Why is the Ex-Dividend Date Significant to Investors?
- The Drone Arms Race: From Battlefield to Balance Sheet
- What is the Australian Securities Exchange (ASX)
- Why Wall Street Is Backing These 3 Comeback Stocks
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Intel’s Breakout Quarter: More Than a Beat, It’s a Declaration
Receive News & Ratings for Genelux Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
